ScripThe new year promises to be one of multifaceted action in India ranging from deal appetite and growing big pharma interest in global capability centers (GCCs), besides some big-ticket launches, to re
ScripIt did not take long for predictions of higher-priced merger-and-acquisition activity in 2025 to come true as Johnson & Johnson’s proposed $14.6bn buyout of Intra-Cellular and its rising neuropsyc
ScripLeading Indian companies such as Dr Reddy’s Laboratories, Sun Pharma and Cipla have deployed distinct strategic approaches to drive their business in China, a tough market to crack by any yardstick bu
Generics BulletinDr Reddy’s Laboratories says it will rely primarily on its in-house capabilities as it looks to break into off-patent GLP-1 agonists in the coming years, with up to 15 targets identified in what it te